Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2125 of 2228 entries
View as:

A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT03082183 Org: User:
Start: 03/28/17 End: 06/20/17 Due: 06/20/18

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01605461 Org: User:
Start: 05/31/12 End: 06/30/12 Due: 06/30/13

Linagliptin Add-on to Insulin Background Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02897349 Org: User:
Start: 09/30/16 End: 01/18/19 Due: 01/18/20

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Phase: N/A Priority: Normal
NCT ID: NCT01396278 Org: User:
Start: 07/01/11 End: 12/14/11 Due: 12/14/12

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Phase: N/A Priority: Normal
NCT ID: NCT01493557 Org: User:
Start: 12/31/11 End: 07/31/14 Due: 07/31/15

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05087992 Org: User:
Start: 11/24/21 End: 11/14/23 Due: 11/14/24

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02254161 Org: User:
Start: 11/30/14 End: 02/28/15 Due: 02/28/16

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT00885118 Org: User:
Start: 04/30/09 End: - Due: -

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT04978506 Org: User:
Start: 09/03/21 End: 07/04/24 Due: 07/04/25

Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02036775 Org: User:
Start: 03/31/14 End: 05/31/14 Due: 05/31/15

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01525628 Org: User:
Start: 04/30/12 End: 10/31/14 Due: 10/31/15

A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04640194 Org: User:
Start: 12/16/20 End: 07/25/22 Due: 07/25/23

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02392455 Org: User:
Start: 03/23/15 End: 06/30/25 Due: 06/30/26

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Phase: N/A Priority: Normal
NCT ID: NCT02483416 Org: User:
Start: 11/19/15 End: 02/27/17 Due: 02/27/18

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Phase: N/A Priority: Normal
NCT ID: NCT00157248 Org: User:
Start: 12/31/03 End: - Due: -

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

Phase: N/A Priority: Normal
NCT ID: NCT01145014 Org: User:
Start: 05/31/10 End: - Due: -

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT06310005 Org: User:
Start: 04/19/24 End: 10/31/24 Due: 10/31/25

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02262598 Org: User:
Start: 09/30/04 End: - Due: -

A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01905111 Org: User:
Start: 07/31/13 End: 08/31/14 Due: 08/31/15

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Phase: N/A Priority: Normal
NCT ID: NCT01694771 Org: User:
Start: 09/30/12 End: 08/31/13 Due: 08/31/14

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase: N/A Priority: Normal
NCT ID: NCT06492135 Org: User:
Start: 08/12/24 End: 04/15/25 Due: 04/15/26

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01540487 Org: User:
Start: 02/29/12 End: 06/30/12 Due: 06/30/13

This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men

Phase: N/A Priority: Normal
NCT ID: NCT03307252 Org: User:
Start: 10/25/17 End: 05/02/18 Due: 05/02/19

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02182453 Org: User:
Start: 06/30/08 End: - Due: -

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02192463 Org: User:
Start: 04/30/06 End: - Due: -